News
Karyopharm Announces Presentations In Endometrial Cancer And Myelofibrosis At The 2024 American Society Of Clinical Oncology Annual Meeting
24 Apr 24
Biotech, News, General
Onco360 Selected As The Preferred National Specialty Pharmacy Partner For Karyopharm's Product XPOVIO, A First-In-Class, XPO-1 Inhibitor
13 Mar 24
Biotech, News, General
HC Wainwright & Co. Maintains Buy on Karyopharm Therapeutics, Lowers Price Target to $8
1 Mar 24
News, Price Target, Analyst Ratings
Karyopharm Therapeutics Q4 2023 GAAP EPS $(0.36) Misses $(0.30) Estimate, Sales $33.75M Miss $35.40M Estimate
29 Feb 24
Earnings, Earnings Misses, News
Earnings Scheduled For February 29, 2024
29 Feb 24
Earnings
Karyopharm Therapeutics's Earnings: A Preview
28 Feb 24
Earnings
12 Health Care Stocks Moving In Tuesday's Intraday Session
6 Feb 24
Movers
12 Health Care Stocks Moving In Monday's Intraday Session
5 Feb 24
Movers
12 Health Care Stocks Moving In Monday's Pre-Market Session
5 Feb 24
Movers
12 Health Care Stocks Moving In Wednesday's After-Market Session
31 Jan 24
Movers
Press releases
Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting
24 Apr 24
Press Releases
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1 Apr 24
Press Releases
Onco360 Selected as the Preferred National Specialty Pharmacy Partner for XPOVIO® (selinexor)
13 Mar 24
Press Releases
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1 Mar 24
Press Releases
Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress
29 Feb 24
Earnings, Press Releases
Karyopharm to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024
22 Feb 24
Press Releases
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1 Feb 24
Offerings, Press Releases